17 GLP-1 agonists may offer benefits related to weight loss and anti-inflammatory effects .17 The case of a 31-year-old female patient with Hurley Stage II HS demonstrated a significant improvement in cutaneous presentation and pain level after treatment with liraglutide
These pens are manufactured in standardized doses, which are stepped up gradually over several months to allow the body to adjust to the medication
Participants maintained weight loss for 23 years with no unexpected safety signals emerging, and cardiovascular event rates remained low or lower than placebo groups
Lindsey Bordone, MD, FAAD Do GLP-1 drugs treat skin disease
Endocrinologists, obesity medicine specialists, and compounding pharmacists evaluating next-generation metabolic therapies will find a detailed review of the triple agonist mechanism, Phase 2 trial data, dosing considerations, and comparisons with approved alternatives in the guide below
Patients on biologic immunosuppressants (infliximab, vedolizumab, ustekinumab) should avoid GLP-1 therapy unless their gastroenterologist explicitly approves, since combining immune-modulating drugs increases infection and flare risk
